Transporters in Drug Development: 2018 ITC Recommendations for Transporters of Emerging Clinical Importance

Affiliations

• ¹ Quantitative Drug Disposition, GlaxoSmithKline, King of Prussia, Pennsylvania, USA.
• ² Drug Metabolism and Pharmacokinetics, Boehringer Ingelheim, Ridgefield, Connecticut, USA.
• ³ Drug Metabolism and Pharmacokinetics, Vertex Pharmaceuticals, Boston, Massachusetts, USA.
• ⁴ Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co., Kenilworth, New Jersey, USA.
• ⁵ Department of Bioengineering and Therapeutic Sciences, Schools of Pharmacy and Medicine, University of California, San Francisco, California, USA.
• ⁶ Division of Clinical Pharmacology, Department of Medicine, Western University, London, ON, Canada.
• ⁷ Clinical Research, Gilead Sciences, Foster City, California, USA.
• ⁸ Department of Clinical Pharmacology & Toxicology, St Vincent's Hospital, Sydney, NSW, Australia & St Vincent's Clinical School, UNSW Sydney, NSW, Australia.
• ⁹ Department of Pharmaceutics, University of Washington, Seattle, Washington, USA.
• ¹⁰ Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.
• ¹¹ Drug Metabolism and Pharmacokinetics, Takeda Pharmaceuticals International, Cambridge, Massachusetts, USA.
• ¹² Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA.
• ¹³ Drug Metabolism Pharmacokinetics & Clinical Pharmacology, Incyte, Wilmington, Delaware, USA.